MAPT and Cognitive impairment: Biomarker studies of amyloidβ1-42 (Aβ1-42), total tau (T-tau) and tau phosphorylated at threonine 181 (P-tau181) in cerebrospinal fluid (CSF) have contributed to understanding the sequence of clinically relevant molecular events contributing to cognitive impairment[13].